FDA Approves Enzalutamide for Nonmetastatic Castration-Sensitive Prostate Cancer

The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.

Related Keywords

Canada ,United States ,America ,Ahsan Arozullah ,Oncology Development At Astellas ,Pfizer ,Pfizer Inc ,European Medicines Agency ,Astellas Pharma Inc ,Strategic Innovation ,Genesiscare United States ,South America ,Efficacy Study ,Enzalutamide Plus Leuprolide ,Patients With Nonmetastatic Prostate ,For Papers ,Pharmacy Times Oncology ,Oncology Development ,New England Journal ,